Dual pancreatic adrenergic and dopaminergic signaling as a therapeutic target of bromocriptine.

ABSTRACT: Bromocriptine is approved as a diabetes therapy, yet its therapeutic mechanisms remain unclear. Though bromocriptine's actions have been mainly attributed to the stimulation of brain dopamine D₂ receptors (D2R), bromocriptine also targets the pancreas. Here, we employ bromocriptine as a tool to elucidate the roles of catecholamine signaling in regulating pancreatic hormone secretion. In β-cells, bromocriptine acts on D2R and α_2A-adrenergic receptor (α_2A-AR) to reduce glucose-stimulated insulin secretion (GSIS). Moreover, in α-cells, bromocriptine acts via D2R to reduce glucagon secretion. α_2A-AR activation by bromocriptine recruits an ensemble of G proteins with no β-arrestin2 recruitment. In contrast, D2R recruits G proteins and β-arrestin2 upon

SUBMITTER: Aslanoglou D 

PROVIDER: S-EPMC9379584 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature